for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cipla Ltd

CIPL.NS

Latest Trade

762.15INR

Change

3.80(+0.50%)

Volume

3,765,555

Today's Range

756.05

 - 

764.80

52 Week Range

355.30

 - 

829.05

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
758.35
Open
760.00
Volume
3,765,555
3M AVG Volume
176.85
Today's High
764.80
Today's Low
756.05
52 Week High
829.05
52 Week Low
355.30
Shares Out (MIL)
806.45
Market Cap (MIL)
611,568.40
Forward P/E
25.58
Dividend (Yield %)
0.59

Next Event

Cipla Ltd Institutional Investor Meeting

Latest Developments

More

Cipla Sept-Quarter Consol Net Profit Rises

Cipla And Stempeutics Collaborate For Launch Of Stempeucel

India's Cipla June-Qtr Consol Net Profit Rises

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cipla Ltd

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.

Industry

Biotechnology & Drugs

Contact Info

Mumbai Central

400013

India

+91.22.24826000

https://www.cipla.com/

Executive Leadership

Yusuf K. Hamied

Non-Executive Chairman of the Board

Umang Vohra

Global Chief Executive Officer, Managing Director, Executive Director

Samina Hamied

Executive Vice Chairman of the Board

M. K. Hamied

Non-Executive Vice Chairman of the Board

Kedar Upadhye

Global Chief Financial Officer

Key Stats

1.71 mean rating - 38 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

147.5K

2019

163.6K

2020

171.3K

2021(E)

191.5K
EPS (INR)

2018

18.460

2019

18.930

2020

19.160

2021(E)

29.553
Price To Earnings (TTM)
33.27
Price To Sales (TTM)
3.37
Price To Book (MRQ)
3.58
Price To Cash Flow (TTM)
20.48
Total Debt To Equity (MRQ)
18.56
LT Debt To Equity (MRQ)
13.71
Return on Investment (TTM)
9.21
Return on Equity (TTM)
7.38

Latest News

Latest News

Indian demand for COVID-19 drug remdesivir rising sharply - Cipla

Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd <CIPL.NS> said on Monday, even as experts remain divided over its effectiveness.

India's shortage of remdesivir is easing, says producer Cipla

India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.

Indian shares rise on pharma boost, Cipla hits record high

Indian shares rose on Monday, with the Nifty 50 extending gains into a fifth session, as a slew of upbeat pharma earnings reports and a rally in defence stocks helped investors look past concerns over surging coronavirus cases.

Indian shares rise as Cipla gains after solid results

Indian shares rose and the Nifty 50 index gained for a fifth straight session on Monday, helped by gains in Cipla Ltd after the drugmaker posted a 21% jump in quarterly profit.

Cipla gets India approval to sell COVID-19 drug favipiravir

Cipla Ltd has received Indian regulatory approval to sell anti-viral drug favipiravir to treat COVID-19, the drugmaker said on Friday, as coronavirus infections in the world's third worst-hit nation show no sign of abating.

Cipla prices its generic remdesivir at $53.34 per vial, below rivals

Cipla Ltd <CIPL.NS> has priced its generic version of remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, the Indian drugmaker said on Wednesday, making it among the lowest priced versions of the COVID-19 treatment available so far globally.

India's Cipla set to undercut rivals with generic remdesivir -sources

Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.

BRIEF-Cipla Commercially Launches Generic Version Of Remdesivir

* CIPLA LTD SAYS COMMERCIALLY LAUNCHES CIPREMI (REMDESIVIR) ON WEDNESDAY -STATEMENT

India's Sovereign Pharma dispatches first batch of remdesivir to Cipla

India's Sovereign Pharma said it has dispatched the first batch of generic remdesivir for drugmaker Cipla Ltd, as the country recorded more than 22,000 new coronavirus cases on Tuesday.

Cipla to price remdesivir version for COVID-19 under 5,000 rupees

Indian drugmaker Cipla Ltd will price its generic version of Gilead Sciences Inc's antiviral drug remdesivir for use in COVID-19 patients at less than 5,000 rupees ($66), the company said.

India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug

India's drug regulator has given Hetero Labs and Cipla Ltd <CIPL.NS> the green light to manufacture and market their generic version of Gilead Sciences Inc's <GILD.O> experimental COVID-19 treatment remdesivir, the Indian pharmaceutical companies said on Sunday.

BRIEF-Cipla Signs Pact With Roche Products (India) Pvt. Ltd

* SIGNS DISTRIBUTION AGREEMENT WITH ROCHE PRODUCTS (INDIA) PVT. LTD

India's Zydus Cadila to make Gilead's potential COVID-19 drug remdesivir

Indian drugmaker Zydus Cadila said on Friday it signed a non-exclusive licensing pact with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials.

BRIEF-Cipla Ltd -Gets Final Approval For Generic Version Of Migranal

* CIPLA LTD -RECEIVES FINAL APPROVAL FOR GENERIC VERSION OF MIGRANAL® (DIHYDROERGOTAMINE MESYLATE NASAL SPRAY 4MG/ML) Source text for Eikon: Further company coverage:

Indian shares fall as economic package fails to impress; Reliance rises

Indian shares slipped on Monday as investors were unimpressed by the government's economic relief measures and coronavirus cases continued to rise steadily, while a boost in Reliance Industries and Cipla limited losses.

BRIEF-Cipla Files ANDA For Generic Version Of GSK's Advair Diskus

* CIPLA FILES ANDA FOR GENERIC VERSION OF GSK'S ADVAIR DISKUS Source text for Eikon: Further company coverage:

BRIEF-Cipla Ltd - Approved Raising Of Funds Of Upto 30 Billion Rupees

* CIPLA LTD - APPROVED RAISING OF FUNDS OF UPTO 30 BILLION RUPEES Source text for Eikon: Further company coverage:

BRIEF-India's Cipla March Quarter Consol Net Profit Falls

* MARCH QUARTER CONSOL NET PROFIT 2.46 BILLION RUPEES VERSUS PROFIT OF 3.67 BILLION RUPEES YEAR AGO

BRIEF-Cipla Ltd Signs Pact With Gilead For COVID-19 Drug Remdesivir

* CIPLA LIMITED ENTERS INTO A LICENSING AGREEMENT WITH GILEAD TO EXPAND ACCESS TO COVID-19 TREATMENT Source text for Eikon: Further company coverage:

BRIEF-Gilead Says Signed Non-Exclusive Voluntary Licensing Agreements With 5 Generic Pharmaceutical Manufacturers Based In India, Pakistan To Further Expand Supply Of Remdesivir

* GILEAD SCIENCES - SIGNED NON-EXCLUSIVE VOLUNTARY LICENSING AGREEMENTS WITH 5 GENERIC PHARMACEUTICAL MANUFACTURERS BASED IN INDIA, PAKISTAN TO FURTHER EXPAND SUPPLY OF REMDESIVIR

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up